Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Treasury Shares (2020 - 2025)

Maravai Lifesciences Holdings has reported Treasury Shares over the past 6 years, most recently at $11.6 million for Q4 2025.

  • Quarterly results put Treasury Shares at $11.6 million for Q4 2025, up 46.1% from a year ago — trailing twelve months through Dec 2025 was $11.6 million (up 46.1% YoY), and the annual figure for FY2025 was $11.6 million, up 46.1%.
  • Treasury Shares for Q4 2025 was $11.6 million at Maravai Lifesciences Holdings, up from $7.9 million in the prior quarter.
  • Over the last five years, Treasury Shares for MRVI hit a ceiling of $11.6 million in Q4 2025 and a floor of $159000.0 in Q4 2021.
  • Median Treasury Shares over the past 5 years was $3.9 million (2023), compared with a mean of $5.0 million.
  • Biggest five-year swings in Treasury Shares: tumbled 54.44% in 2021 and later surged 737.11% in 2022.
  • Maravai Lifesciences Holdings' Treasury Shares stood at $159000.0 in 2021, then surged by 737.11% to $1.3 million in 2022, then soared by 196.32% to $3.9 million in 2023, then soared by 101.47% to $7.9 million in 2024, then skyrocketed by 46.1% to $11.6 million in 2025.
  • The last three reported values for Treasury Shares were $11.6 million (Q4 2025), $7.9 million (Q4 2024), and $3.9 million (Q4 2023) per Business Quant data.